These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 10173228)
1. The immortality enzyme. A newly discovered gene may help scientists combat cancer and ailments linked to aging. Nash JM Time; 1997 Sep; 150(9):65. PubMed ID: 10173228 [No Abstract] [Full Text] [Related]
2. [Telomerase and cancer]. Soria JC; Ducray C; Vielh P Ann Pathol; 1998 Nov; 18(5):391-403. PubMed ID: 9864575 [No Abstract] [Full Text] [Related]
3. Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies. Keith WN; Bilsland A; Hardie M; Evans TR Nat Clin Pract Oncol; 2004 Dec; 1(2):88-96. PubMed ID: 16264826 [TBL] [Abstract][Full Text] [Related]
5. Telomere biology of pediatric cancer. Tabori U; Dome JS Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease. Tárkányi I; Aradi J Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408 [TBL] [Abstract][Full Text] [Related]
7. Telomere biology and the molecular basis of aging. Parwaresch R; Krupp G Arkh Patol; 2002; 64(3):37-9. PubMed ID: 15338723 [TBL] [Abstract][Full Text] [Related]
8. Telomeres and telomerase: Biological and clinical importance in dogs. Nasir L Vet J; 2008 Feb; 175(2):155-63. PubMed ID: 17398127 [TBL] [Abstract][Full Text] [Related]
9. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects. Kelland LR Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745 [TBL] [Abstract][Full Text] [Related]
10. [Telomere dysfunction and telomerase: implications for human pathophysiology during ageing and chronic diseases]. Plentz RR; Rudolph KL Dtsch Med Wochenschr; 2006 Sep; 131(38):2087-90. PubMed ID: 16981080 [No Abstract] [Full Text] [Related]
13. Multiple levels of telomerase regulation. Stewart SA Mol Interv; 2002 Dec; 2(8):481-3. PubMed ID: 14993399 [TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Sharma S; Raymond E; Soda H; Sun D; Hilsenbeck SG; Sharma A; Izbicka E; Windle B; Von Hoff DD Ann Oncol; 1997 Nov; 8(11):1063-74. PubMed ID: 9426325 [TBL] [Abstract][Full Text] [Related]
15. MOV10 as a novel telomerase-associated protein. Nakano M; Kakiuchi Y; Shimada Y; Ohyama M; Ogiwara Y; Sasaki-Higashiyama N; Yano N; Ikeda F; Yamada E; Iwamatsu A; Kobayashi K; Nishiyama K; Ichikawa S; Kaji K; Ide T; Murofushi H; Murakami-Murofushi K Biochem Biophys Res Commun; 2009 Oct; 388(2):328-32. PubMed ID: 19665004 [TBL] [Abstract][Full Text] [Related]
16. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Seimiya H; Muramatsu Y; Ohishi T; Tsuruo T Cancer Cell; 2005 Jan; 7(1):25-37. PubMed ID: 15652747 [TBL] [Abstract][Full Text] [Related]
17. Telomeres and telomerase as targets for anticancer drug development. Olaussen KA; Dubrana K; Domont J; Spano JP; Sabatier L; Soria JC Crit Rev Oncol Hematol; 2006 Mar; 57(3):191-214. PubMed ID: 16469501 [TBL] [Abstract][Full Text] [Related]
18. Telomeres, telomerase, and immortality. Rhyu MS J Natl Cancer Inst; 1995 Jun; 87(12):884-94. PubMed ID: 7666477 [TBL] [Abstract][Full Text] [Related]
19. Telomere instability and cancer. Londoño-Vallejo JA Biochimie; 2008 Jan; 90(1):73-82. PubMed ID: 17728038 [TBL] [Abstract][Full Text] [Related]
20. The level of telomere dysfunction determines the efficacy of telomerase-based therapeutics in a lung cancer cell line. Pantic M; Zimmermann S; Waller CF; Martens UM Int J Oncol; 2005 May; 26(5):1227-32. PubMed ID: 15809713 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]